Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials

德诺苏马布 唑来膦酸 医学 肿瘤科 内科学 骨质疏松症
作者
Allan Lipton,Karim Fizazi,Alison Stopeck,David H. Henry,Janet E. Brown,Denise A. Yardley,Gary Richardson,Salvatore Siena,Pablo Maroto,Michael Clemens,Boris Bilynskyy,Veena Charu,Philippe Beuzeboc,Michael Rader,María Eugenia Ibarrarán Viniegra,Fred Saad,Chunlei Ke,Ada Braun,Susie Jun
出处
期刊:European Journal of Cancer [Elsevier BV]
卷期号:48 (16): 3082-3092 被引量:588
标识
DOI:10.1016/j.ejca.2012.08.002
摘要

Patients with bone metastases from advanced cancer often experience skeletal-related events (SRE), which cause substantial pain and morbidity. Denosumab, a fully human monoclonal antibody that inhibits RANK Ligand (RANKL), is a novel bone-targeted agent with a distinct mechanism of action relative to the bisphosphonate zoledronic acid, for prevention of SRE. This pre-planned analysis evaluates the efficacy and safety of denosumab versus zoledronic acid across three pivotal studies.Patient-level data from three identically designed, randomised, double-blind, active-controlled, phase 3 trials of patients with breast cancer, prostate cancer, other solid tumours or multiple myeloma were combined. End-points included time to first SRE, time to first and subsequent (multiple) SRE, adverse events, time to disease progression and overall survival.Denosumab was superior to zoledronic acid in delaying time to first on-study SRE by a median 8.21months, reducing the risk of a first SRE by 17% (hazard ratio, 0.83 [95% confidence interval (CI): 0.76-0.90]; P<0.001). Efficacy was demonstrated for first and multiple events and across patient subgroups (prior SRE status; age). Disease progression and overall survival were similar between the treatments. In contrast to zoledronic acid, denosumab did not require monitoring or dose modification/withholding based on renal status, and was not associated with acute-phase reactions. Hypocalcaemia was more common for denosumab. Osteonecrosis of the jaw occurred at a similar rate (P=0.13).Denosumab was superior to zoledronic acid in preventing SRE with favourable safety and convenience in patients with bone metastases from advanced cancer.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
芹菜完成签到,获得积分10
3秒前
热心十八完成签到,获得积分10
3秒前
小兔叽完成签到 ,获得积分10
7秒前
Allen完成签到,获得积分10
8秒前
force完成签到 ,获得积分10
8秒前
asdasdf完成签到,获得积分10
9秒前
chic完成签到 ,获得积分10
9秒前
红颜如梦完成签到 ,获得积分10
9秒前
闪闪慕蕊完成签到 ,获得积分10
10秒前
熙可檬完成签到 ,获得积分10
10秒前
充电宝的应助被ping采纳,获得10
10秒前
wawaeryu完成签到,获得积分10
11秒前
hjj完成签到 ,获得积分10
13秒前
余闻问完成签到,获得积分10
14秒前
14秒前
san完成签到,获得积分10
15秒前
Health完成签到 ,获得积分10
17秒前
2520完成签到 ,获得积分10
18秒前
MJMO完成签到,获得积分10
18秒前
相宜完成签到,获得积分10
19秒前
墨玖辰完成签到,获得积分10
20秒前
高高的哈密瓜完成签到 ,获得积分10
21秒前
阿臭der完成签到 ,获得积分10
21秒前
搬砖的化学男完成签到 ,获得积分10
21秒前
sun完成签到,获得积分10
22秒前
zhouyms完成签到,获得积分10
24秒前
神通广大的MOMO完成签到,获得积分10
25秒前
美满的机器猫完成签到,获得积分10
28秒前
30秒前
Gabi完成签到,获得积分10
30秒前
34秒前
WWW完成签到 ,获得积分10
34秒前
waldoe完成签到,获得积分10
34秒前
35秒前
Laser_eyes完成签到,获得积分10
35秒前
大胆的弼完成签到,获得积分10
35秒前
36秒前
GGG完成签到 ,获得积分10
36秒前
朴素傲松完成签到,获得积分10
36秒前
37秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8185537
求助须知:如何正确求助?哪些是违规求助? 9574270
关于积分的说明 21834871
捐赠科研通 7783247
什么是DOI,文献DOI怎么找? 3434577
关于科研通互助平台的介绍 2558951
邀请新用户注册赠送积分活动 2481370